🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

112+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 112 recruiting trials for “Adult hepatocellular carcinoma

NARecruitingNCT06265350

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

👨‍⚕️ Zhimei Hunag, MD, Sun Yat-sen University📍 2 sites📅 Started Feb 2024View details ↗
Phase 2, PHASE3RecruitingNCT06109272

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

👨‍⚕️ ABBVIE INC., AbbVie📍 37 sites📅 Started Jan 2024View details ↗
RecruitingNCT05705219

Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

👨‍⚕️ Ahmed El Kaffas, PhD, University of California, San Diego📍 3 sites📅 Started Dec 2023View details ↗
Phase 2RecruitingNCT06034977

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

👨‍⚕️ Wei-Ting Chen, MD, Chang Gung Memorial Hospital📍 1 site📅 Started Dec 2023View details ↗
RecruitingNCT06117891

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

🏥 Bayer📍 20 sites📅 Started Nov 2023View details ↗
Phase 2RecruitingNCT06133062

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

🏥 Chang Gung Memorial Hospital📍 1 site📅 Started Nov 2023View details ↗
Phase 2RecruitingNCT05440864

Durvalumab and Tremelimumab in Resectable HCC

👨‍⚕️ Gonzalo Sapisochin, MD, Univeristy Health Network📍 3 sites📅 Started Oct 2023View details ↗
RecruitingNCT05263830

Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

👨‍⚕️ Manon ALLAIRE, Dr, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT06060769

Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging

👨‍⚕️ Yaqin Zhang, MD, Ph.D, Fifth Affiliated Hospital, Sun Yat-Sen University📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT06036563

Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing

🏥 Air Force Military Medical University, China📍 8 sites📅 Started Sep 2023View details ↗
Phase 4RecruitingNCT07132515

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

🏥 Mansoura University📍 1 site📅 Started Aug 2023View details ↗
Phase 3RecruitingNCT05862337

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 67 sites📅 Started May 2023View details ↗
Phase 2RecruitingNCT06370065

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

🏥 Tianjin Medical University Cancer Institute and Hospital📍 1 site📅 Started Apr 2023View details ↗
NARecruitingNCT05146297

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

👨‍⚕️ Nina Bickell, Icahn School of Medicine at Mount Sinai📍 3 sites📅 Started Apr 2023View details ↗
Phase 1RecruitingNCT05791448

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

👨‍⚕️ Anthony B El-Khoueiry, MD, University of Southern California📍 2 sites📅 Started Mar 2023View details ↗
Phase 2RecruitingNCT05809869

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

👨‍⚕️ Victor Ho-Fun Lee, MD, The University of Hong Kong📍 1 site📅 Started Feb 2023View details ↗
Phase 3RecruitingNCT05489289

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

👨‍⚕️ Jia Fan, Ph.D., Fudan University📍 1 site📅 Started Jan 2023View details ↗
RecruitingNCT06806579

Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

👨‍⚕️ Francesco Tovoli, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 24 sites📅 Started Dec 2022View details ↗
Phase 1, PHASE2RecruitingNCT05652920

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

🏥 OriCell Therapeutics Co., Ltd.📍 7 sites📅 Started Dec 2022View details ↗
Phase 2, PHASE3RecruitingNCT05408221

the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma

👨‍⚕️ Cai Jian qiang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 5 sites📅 Started Nov 2022View details ↗
← PreviousPage 4 of 6Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →